Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
COR 
Cencora Inc. (COR)
Today’s top pick
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: COR (3-star) is a STRONG-BUY. BUY since 48 days. Profits (12.14%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 29.15% | Avg. Invested days 50 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 53.87B USD | Price to earnings Ratio 39.39 | 1Y Target Price 281.09 |
Price to earnings Ratio 39.39 | 1Y Target Price 281.09 | ||
Volume (30-day avg) 1674632 | Beta 0.5 | 52 Weeks Range 213.34 - 280.70 | Updated Date 04/1/2025 |
52 Weeks Range 213.34 - 280.70 | Updated Date 04/1/2025 | ||
Dividends yield (FY) 0.79% | Basic EPS (TTM) 7.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.46% | Operating Margin (TTM) 0.97% |
Management Effectiveness
Return on Assets (TTM) 2.86% | Return on Equity (TTM) 198.15% |
Valuation
Trailing PE 39.39 | Forward PE 18.15 | Enterprise Value 58793821431 | Price to Sales(TTM) 0.18 |
Enterprise Value 58793821431 | Price to Sales(TTM) 0.18 | ||
Enterprise Value to Revenue 0.19 | Enterprise Value to EBITDA 18.29 | Shares Outstanding 193712992 | Shares Floating 182697040 |
Shares Outstanding 193712992 | Shares Floating 182697040 | ||
Percent Insiders 5.72 | Percent Institutions 92.69 |
Analyst Ratings
Rating 3.94 | Target Price 266.34 | Buy 1 | Strong Buy 8 |
Buy 1 | Strong Buy 8 | ||
Hold 7 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cencora Inc.
Company Overview
History and Background
Cencora Inc., formerly AmerisourceBergen, was founded in 2001 through the merger of Bergen Brunswig and AmeriSource Health Corporation. Its roots extend back to the 19th century with predecessor companies. The company has grown through organic expansion and strategic acquisitions to become a leading global pharmaceutical distributor.
Core Business Areas
- Pharmaceutical Distribution: Distributes branded and generic pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies.
- Specialty Pharmaceutical Services: Provides services for specialty pharmaceuticals, including distribution, patient support, and reimbursement services.
- Global Sourcing and Manufacturing: Sources and manufactures pharmaceuticals and related products globally.
Leadership and Structure
Steven H. Collis is the Chairman, President & CEO. The company operates with a functional organizational structure, dividing operations into various segments such as Pharmaceutical Distribution, Specialty Group, and International Healthcare Solutions.
Top Products and Market Share
Key Offerings
- Branded Pharmaceuticals: Distribution of branded prescription drugs. Competitors: McKesson, Cardinal Health. Market share not easily attributable to specific product line but considered significant within overall distribution market.
- Competitors: McKesson Corporation (MCK),Cardinal Health (CAH)
- Competitors: McKesson Corporation (MCK),Cardinal Health (CAH)
- Generic Pharmaceuticals: Distribution of generic prescription drugs. Competitors: McKesson, Cardinal Health. Market share not easily attributable to specific product line but considered significant within overall distribution market.
- Competitors: McKesson Corporation (MCK),Cardinal Health (CAH),Cigna (CI)
- Specialty Pharmaceuticals: Distribution and related services for specialty drugs. Competitors: McKesson, Cardinal Health, CuraScript SD (owned by Cigna).
Market Dynamics
Industry Overview
The pharmaceutical distribution industry is characterized by high regulation, consolidation, and a focus on supply chain efficiency. The industry is crucial in delivering medications from manufacturers to healthcare providers and patients.
Positioning
Cencora Inc. is one of the top three pharmaceutical distributors in the US, with a significant market share and a strong focus on specialty pharmaceuticals and international expansion. Competitive advantages include its scale, distribution network, and relationships with manufacturers and pharmacies.
Total Addressable Market (TAM)
The global pharmaceutical distribution market is estimated to be worth hundreds of billions of dollars. Cencora Inc. is well-positioned to capture a significant portion of this TAM through its diverse offerings and geographic reach.
Upturn SWOT Analysis
Strengths
- Large scale and market share
- Extensive distribution network
- Strong relationships with manufacturers and pharmacies
- Focus on specialty pharmaceuticals
- International presence
Weaknesses
- Reliance on a few large customers
- Exposure to regulatory changes
- Pricing pressures from manufacturers and payers
- High debt levels (can vary)
- Dependence on key suppliers
Opportunities
- Growing demand for specialty pharmaceuticals
- Expansion into emerging markets
- Increased focus on supply chain efficiency
- Development of value-added services
- Acquisitions of smaller distributors
Threats
- Increased competition from other distributors
- Drug pricing regulations
- Disruptions in the supply chain
- Cybersecurity risks
- Economic downturn
Competitors and Market Share
Key Competitors
- McKesson Corporation (MCK)
- Cardinal Health (CAH)
- Option Care Health (OPCH)
Competitive Landscape
Cencora Inc. competes with McKesson and Cardinal Health for market share. Cencora's focus on specialty pharmaceuticals provides a competitive advantage. However, all three companies face similar regulatory and pricing pressures.
Major Acquisitions
PharmaLex Group
- Year: 2020
- Acquisition Price (USD millions): 1280
- Strategic Rationale: Expanded Cencora's presence in the European regulatory consulting and services market, strengthening its global healthcare solutions portfolio.
Growth Trajectory and Initiatives
Historical Growth: Cencora Inc. has historically grown through organic expansion and acquisitions. Growth has been driven by increased demand for pharmaceuticals and healthcare services.
Future Projections: Future growth projections are based on analyst estimates. Projections suggest continued growth in revenue and earnings, driven by specialty pharmaceuticals and international expansion.
Recent Initiatives: Recent strategic initiatives may include acquisitions, partnerships, and investments in new technologies to improve efficiency and expand service offerings.
Summary
Cencora Inc. is a strong player in the pharmaceutical distribution market, benefiting from its large scale and focus on specialty pharmaceuticals. The company faces challenges related to regulatory changes and pricing pressures. Strategic acquisitions and international expansion are key to its growth trajectory. Its competitive advantages stem from its well-established distribution network and strong customer relationships, but it needs to monitor for potential disruptions in the supply chain.
Similar Companies
- MCK
- CAH
- WBA
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Data is based on available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cencora Inc.
Exchange NYSE | Headquaters Conshohocken, PA, United States | ||
IPO Launch date 1995-04-04 | President, CEO & Director Dr. Robert P. Mauch Ph.D., PharmD | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 46000 | Website https://www.cencora.com |
Full time employees 46000 | Website https://www.cencora.com | ||
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.